• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Evaluating serum free light chain ratio as a biomarker in multiple myeloma.

作者信息

Akhlaghi Theresia, Maclachlan Kylee, Korde Neha, Mailankody Sham, Lesokhin Alexander, Hassoun Hani, Lu Sydney X, Patel Dhwani, Shah Urvi, Tan Carlyn, Derkach Andriy, Lahoud Oscar, Landau Heather J, Shah Gunjan L, Scordo Michael, Chung David J, Giralt Sergio A, Usmani Saad Z, Landgren Ola, Hultcrantz Malin

机构信息

Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.

出版信息

Haematologica. 2025 Feb 1;110(2):493-497. doi: 10.3324/haematol.2024.285531.

DOI:10.3324/haematol.2024.285531
PMID:39363855
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11788616/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/897d/11788616/1bfb7ab04cc0/110493.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/897d/11788616/1bfb7ab04cc0/110493.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/897d/11788616/1bfb7ab04cc0/110493.fig1.jpg

相似文献

1
Evaluating serum free light chain ratio as a biomarker in multiple myeloma.评估血清游离轻链比值作为多发性骨髓瘤的生物标志物。
Haematologica. 2025 Feb 1;110(2):493-497. doi: 10.3324/haematol.2024.285531.
2
[The roles of serum free light chain ratio in the diagnosis and prognosis of newly diagnosed multiple myeloma].[血清游离轻链比值在新诊断多发性骨髓瘤诊断及预后中的作用]
Zhonghua Xue Ye Xue Za Zhi. 2016 May 14;37(5):377-82. doi: 10.3760/cma.j.issn.0253-2727.2016.05.005.
3
Light Chain Multiple Myeloma: High Serum Free Light Chain Concentrations Portend Renal Damage and Poorer Survival.轻链型多发性骨髓瘤：血清游离轻链浓度高预示着肾脏损伤和预后不良。
J Appl Lab Med. 2021 Nov 1;6(6):1592-1600. doi: 10.1093/jalm/jfab090.
4
Serum Free Light-Chain Ratio at Diagnosis Is Associated with Early Renal Damage in Multiple Myeloma: A Case Series Real-World Study.诊断时血清游离轻链比值与多发性骨髓瘤早期肾损伤相关：一项病例系列真实世界研究
Biomedicines. 2022 Jul 10;10(7):1657. doi: 10.3390/biomedicines10071657.
5
Measurement of free kappa and lambda chains in serum and the significance of their ratio in patients with multiple myeloma.血清中游离κ链和λ链的检测及其比值在多发性骨髓瘤患者中的意义。
Br J Haematol. 1992 Jun;81(2):223-30. doi: 10.1111/j.1365-2141.1992.tb08211.x.
6
Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.血清游离轻链比值作为高危冒烟型多发性骨髓瘤的生物标志物。
Leukemia. 2013 Apr;27(4):941-6. doi: 10.1038/leu.2012.296. Epub 2012 Oct 16.
7
Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma.血清游离轻链与尿液电泳在检测轻链型和完整免疫球蛋白型多发性骨髓瘤中单克隆免疫球蛋白轻链成分方面的比较。
Haematologica. 2016 Mar;101(3):356-62. doi: 10.3324/haematol.2015.126797. Epub 2015 Dec 3.
8
Serum free light chain assays not total light chain assays are the standard of care to assess Monoclonal Gammopathies.血清游离轻链检测而非总轻链检测是评估单克隆丙种球蛋白病的治疗标准。
Rev Bras Hematol Hemoter. 2016 Jan-Feb;38(1):37-43. doi: 10.1016/j.bjhh.2015.11.003. Epub 2016 Feb 1.
9
Evaluation of Correlation between Serum Free Light-Chain Assay and Bone Marrow Study in Multiple Myeloma Patients.多发性骨髓瘤患者血清游离轻链检测与骨髓检查之间的相关性评估
Int J Hematol Oncol Stem Cell Res. 2021 Jul 1;15(3):152-159. doi: 10.18502/ijhoscr.v15i3.6845.
10
The Missing M Band: Is it Really Non Secretory Multiple Myeloma?缺失的M带：它真的是非分泌型多发性骨髓瘤吗？
EJIFCC. 2025 Feb 28;36(1):74-82. eCollection 2025 Mar.

引用本文的文献

1
Performance and comparison of FLCCheck: a novel serum free light chain assay for the Auxiliary Diagnosis of Multiple Myeloma.FLCCheck的性能与比较：一种用于多发性骨髓瘤辅助诊断的新型血清游离轻链检测方法
Eur J Med Res. 2025 Aug 4;30(1):706. doi: 10.1186/s40001-025-02984-8.
2
Performance Characteristics and Limitations of the Available Assays for the Detection and Quantitation of Monoclonal Free Light Chains and New Emerging Methodologies.用于检测和定量单克隆游离轻链的现有检测方法的性能特征与局限性以及新兴方法
Antibodies (Basel). 2024 Mar 11;13(1):19. doi: 10.3390/antib13010019.

本文引用的文献

1
Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100.单克隆蛋白尿预测游离轻链比值≥100 的无症状多发性骨髓瘤的进展风险。
Leukemia. 2022 May;36(5):1429-1431. doi: 10.1038/s41375-022-01529-w. Epub 2022 Feb 21.
2
Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities.全基因组测序揭示进展性与稳定性骨髓瘤前体疾病是两种截然不同的实体。
Nat Commun. 2021 Mar 25;12(1):1861. doi: 10.1038/s41467-021-22140-0.
3
The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma.
冒烟型骨髓瘤的分子构成强调了导致多发性骨髓瘤的进化途径。
Nat Commun. 2021 Jan 12;12(1):293. doi: 10.1038/s41467-020-20524-2.
4
Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression.冒烟型多发性骨髓瘤的基因组分析确定了疾病进展风险较高的患者。
J Clin Oncol. 2020 Jul 20;38(21):2380-2389. doi: 10.1200/JCO.20.00437. Epub 2020 May 22.
5
Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling.冒烟型多发性骨髓瘤的风险分层：游离轻链和基于群组的轨迹建模的预测价值。
Blood Adv. 2018 Jun 26;2(12):1470-1479. doi: 10.1182/bloodadvances.2018016998.
6
Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.纳入修订后 IMWG 诊断标准的冒烟型多发性骨髓瘤的风险分层。
Blood Cancer J. 2018 Jun 12;8(6):59. doi: 10.1038/s41408-018-0077-4.
7
Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study.冒烟型多发性骨髓瘤进展的危险因素：一项基于丹麦人群的队列研究。
Eur J Haematol. 2016 Sep;97(3):303-9. doi: 10.1111/ejh.12728. Epub 2016 Feb 5.
8
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.国际骨髓瘤工作组更新了多发性骨髓瘤的诊断标准。
Lancet Oncol. 2014 Nov;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26.
9
Classifying ultra-high risk smoldering myeloma.超高风险冒烟型骨髓瘤的分类
Leukemia. 2015 Mar;29(3):751-3. doi: 10.1038/leu.2014.313. Epub 2014 Nov 5.
10
Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease.广泛的骨髓浸润和异常的游离轻链比值可识别出无症状骨髓瘤患者，这些患者进展为有症状疾病的风险较高。
Leukemia. 2013 Apr;27(4):947-53. doi: 10.1038/leu.2012.309. Epub 2012 Nov 6.